As of June 20, 2025, Genetron Holdings Ltd (GTH) reports a EV/EBITDA of -0.82.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Genetron Holdings Ltd's EV/EBITDA to Peers
To better understand Genetron Holdings Ltd's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Genetron Holdings Ltd (GTH) | -0.82 |
| Innovent Biologics Inc (1801.HK) | 483.46 |
| Walvax Biotechnology Co Ltd (300142.SZ) | 308.81 |
| Bloomage Biotechnology Corp Ltd (688363.SS) | 205.97 |
| Chongqing Zhifei Biological Products Co Ltd (300122.SZ) | 126.51 |
| Shenzhen Kangtai Biological Products Co Ltd (300601.SZ) | 115.02 |
Compared to its competitors, Genetron Holdings Ltd's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.